Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?

Group 1 - Aquestive Therapeutics (AQST) shares increased by 16% to $6.09, with a notable trading volume, following a 93% gain over the past four weeks [1] - The stock price surge is linked to the successful achievement of primary and secondary endpoints in a phase III clinical study for Anaphylm (epinephrine) Sublingual Film, aimed at treating severe allergic reactions [1] - The company plans to file a new drug application for Anaphylm by the end of 2024, which is expected to further influence stock performance [1] Group 2 - The upcoming quarterly report for Aquestive Therapeutics is projected to show a loss of $0.09 per share, a year-over-year decline of 181.8%, with revenues expected to reach $12.47 million, reflecting a 12% increase from the previous year [2] - The consensus EPS estimate for the quarter has been revised 13.3% higher in the last 30 days, indicating a potential for price appreciation [2] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook compared to other stocks in the same industry [3] Group 3 - Collegium Pharmaceutical (COLL), a peer in the Zacks Medical - Drugs industry, saw a 2.8% increase in its stock price, with a 12% return over the past month [3] - Collegium's consensus EPS estimate has risen by 11.9% over the past month, indicating positive momentum in earnings expectations [3] - Collegium Pharmaceutical holds a Zacks Rank of 1 (Strong Buy), contrasting with Aquestive's current ranking [3]